Elizabeth Gyamfi1,2,3, Charles A Narh4,5, Charles Quaye4, Adiza Abbass2,3, Bartholomew Dzudzor1, Lydia Mosi6,7. 1. Department of Medical Biochemistry, University of Ghana Medical School, Korle Bu, Accra, Ghana. 2. Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana. 3. West African Center for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Accra, Ghana. 4. Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana. 5. Burnet Institute for Medical Research, Melbourne, Australia. 6. Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana. lmosi@ug.edu.gh. 7. West African Center for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Accra, Ghana. lmosi@ug.edu.gh.
Abstract
BACKGROUND: Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans and is the second most common mycobacterial disease after tuberculosis in Ghana and Côte d'Ivoire. M. ulcerans produces mycolactone, an immunosuppressant macrolide toxin, responsible for the characteristic painless nature of the infection. Secondary infection of ulcers before, during and after treatment has been associated with delayed wound healing and resistance to streptomycin and rifampicin. However, not much is known of the bacteria causing these infections as well as antimicrobial drugs for treating the secondary microorganism. This study sought to identify secondary microbial infections in BU lesions and to determine their levels of antibiotic resistance due to the prolonged antibiotic therapy required for Buruli ulcer. RESULTS: Swabs from fifty-one suspected BU cases were sampled in the Amansie Central District from St. Peters Hospital (Jacobu) and through an active case surveillance. Forty of the samples were M. ulcerans (BU) positive. Secondary bacteria were identified in all sampled lesions (N = 51). The predominant bacteria identified in both BU and Non-BU groups were Staphylococci spp and Bacilli spp. The most diverse secondary bacteria were detected among BU patients who were not yet on antibiotic treatment. Fungal species identified were Candida spp, Penicillium spp and Trichodema spp. Selected secondary bacteria isolates were all susceptible to clarithromycin and amikacin among both BU and Non-BU patients. Majority, however, had high resistance to streptomycin. CONCLUSIONS: Microorganisms other than M. ulcerans colonize and proliferate on BU lesions. Secondary microorganisms of BU wounds were mainly Staphylococcus spp, Bacillus spp and Pseudomonas spp. These secondary microorganisms were less predominant in BU patients under treatment compared to those without treatment. The delay in healing that are experienced by some BU patients could be as a result of these bacteria and fungi colonizing and proliferating in BU lesions. Clarithromycin and amikacin are likely suitable drugs for clearance of secondary infection of Buruli ulcer.
BACKGROUND:Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans and is the second most common mycobacterial disease after tuberculosis in Ghana and Côte d'Ivoire. M. ulcerans produces mycolactone, an immunosuppressant macrolide toxin, responsible for the characteristic painless nature of the infection. Secondary infection of ulcers before, during and after treatment has been associated with delayed wound healing and resistance to streptomycin and rifampicin. However, not much is known of the bacteria causing these infections as well as antimicrobial drugs for treating the secondary microorganism. This study sought to identify secondary microbial infections in BU lesions and to determine their levels of antibiotic resistance due to the prolonged antibiotic therapy required for Buruli ulcer. RESULTS: Swabs from fifty-one suspected BU cases were sampled in the Amansie Central District from St. Peters Hospital (Jacobu) and through an active case surveillance. Forty of the samples were M. ulcerans (BU) positive. Secondary bacteria were identified in all sampled lesions (N = 51). The predominant bacteria identified in both BU and Non-BU groups were Staphylococci spp and Bacilli spp. The most diverse secondary bacteria were detected among BU patients who were not yet on antibiotic treatment. Fungal species identified were Candidaspp, Penicilliumspp and Trichodema spp. Selected secondary bacteria isolates were all susceptible to clarithromycin and amikacin among both BU and Non-BU patients. Majority, however, had high resistance to streptomycin. CONCLUSIONS: Microorganisms other than M. ulcerans colonize and proliferate on BU lesions. Secondary microorganisms of BU wounds were mainly Staphylococcusspp, Bacillusspp and Pseudomonasspp. These secondary microorganisms were less predominant in BU patients under treatment compared to those without treatment. The delay in healing that are experienced by some BU patients could be as a result of these bacteria and fungi colonizing and proliferating in BU lesions. Clarithromycin and amikacin are likely suitable drugs for clearance of secondary infection of Buruli ulcer.
Authors: L Toutous Trellu; P Nkemenang; B Mboua; E Tschanz; G Ehounou; E Comte; J F Etard; E Tabah Njih; Y Mueller Journal: Med Sante Trop Date: 2013-05-01
Authors: Douglas S Walsh; Fredrick Eyase; David Onyango; Alfred Odindo; Walter Otieno; John N Waitumbi; Wallace D Bulimo; David C Schnabel; Wayne M Meyers; Françoise Portaels Journal: Am J Trop Med Hyg Date: 2009-12 Impact factor: 2.345
Authors: Richard Phillips; Fred S Sarfo; Laure Guenin-Macé; Jérémie Decalf; Mark Wansbrough-Jones; Matthew L Albert; Caroline Demangel Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Charles A Narh; Lydia Mosi; Charles Quaye; Christelle Dassi; Daniele O Konan; Samuel C K Tay; Dziedzom K de Souza; Daniel A Boakye; Bassirou Bonfoh Journal: PLoS Negl Trop Dis Date: 2015-01-22
Authors: Marcellin B Tano; Christelle Dassi; Lydia Mosi; Marina Koussémon; Bassirou Bonfoh Journal: Int J Environ Res Public Health Date: 2017-02-11 Impact factor: 3.390